深圳华大智造科技股份有限公司 第二届董事会第二十次会议决议公告

Group 1 - The company plans to sell 100% equity of its wholly-owned subsidiary Complete Genomics, Inc. (CGI) to Swiss Rockets AG for approximately $50 million, with the final price subject to the delivery conditions [1][30][36] - The board of directors unanimously approved the sale and the adjustment of the CoolMPS licensing agreement during the 20th meeting of the second board session [4][5][38] - The transaction aims to improve the company's financial performance by divesting a loss-making unit and generating significant cash flow [36][48] Group 2 - The company has entered into a licensing agreement with Swiss Rockets for its CoolMPS sequencing technology, granting exclusive rights outside the Asia-Pacific and Greater China regions [2][31] - An amendment to the licensing agreement includes the addition of StandardMPS sequencing technology, providing Swiss Rockets with exclusive rights in the U.S. and Canada [3][32] - The company will receive a total of at least $120 million in licensing fees over time, including an upfront payment of $20 million already received [34][36] Group 3 - The transaction is expected to enhance the company's overall profitability and operational efficiency by reducing losses associated with the divested business unit [36][48] - The company will retain permanent, free, and irrevocable rights to 205 patents held by CGI, ensuring continuity in its technology framework [4][36][53] - The strategic partnership with Swiss Rockets is anticipated to facilitate the company's expansion into the North American market while optimizing global resource allocation [36][48]